Fracture risk a class effect of thiazolidinediones in women

摘要: Treatment with thiazolidinediones (glitazones) for type 2 diabetes has been found to increase the risk of fractures in women. Pioglitazone now joined rosiglitazone, as subject a US Food and Drug Administration alert fracture risk. Takeda, makers pioglitazone (contained Actos, Actosplusmet, Duetact), GlaxoSmithKline, rosiglitazone Avandia Avandamet), have contacted healthcare professionals setting out evidence on recommending that they consider this when starting or treating women these agents. The statement …